Name: 글로벌 시장 동향
SKU: BT6460
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 호흡기세포융합바이러스(RSV) 치료제 시장은 2022년 12억 달러 규모에 도달했으며, 2030년까지 24억 달러 규모로 성장할 것으로 예상됩니다. 전 세계 RSV 치료제 시장은 예측 기간(2023-2030년) 동안 연평균 10.2%의 성장률을 보일 것으로 전망됩니다. RSV 관련 입원 환자 수 증가와 신약 임상 시험 확대가 RSV 치료제 시장 수요 증가를 견인하고 있습니다.
RSV는 신생아와 어린아이의 호흡기에 주로 영향을 미치는 흔한 바이러스 감염입니다. RSV는 노인이나 면역력이 저하된 사람들에게도 심각한 호흡기 감염을 일으킬 수 있습니다. RSV는 영유아 입원의 가장 흔한 원인입니다. 효과적인 치료법은 감염의 심각성을 완화하고 입원 필요성을 줄여 의료 시스템에 대한 부담을 완화할 수 있습니다.

시장 동향
주요 기업들의 임상 시험 증가가 시장 성장을 견인할 것으로 예상됩니다.
주요 기업들의 임상 시험 증가가 시장 성장을 촉진할 것으로 전망됩니다. 예를 들어, 아스클레티스 파마(Ascletis Pharma Inc.)에 따르면, 중국 국가약품감독관리국(NMPA)은 2023년 5월 8일 호흡기세포융합바이러스(RSV) 감염 치료를 위한 ASC10의 2a상 임상 시험을 승인했습니다.
이번 연구 결과에 따라, 경증 또는 중등도 RSV 감염 환자를 대상으로 ASC10 정제의 항바이러스 효능, 안전성, 내약성 및 약동학을 평가하기 위해 800mg의 ASC10을 1일 2회 투여하는 무작위 이중맹검 위약 대조 2a상 연구가 진행될 예정입니다. 임상 시험 증가는 시장 성장을 더욱 촉진할 것입니다.
유망한 결과를 보이는 강력한 제품 파이프라인이 시장 성장을 견인할 전망입니다.
제약 회사들이 RSV 퇴치를 위해 연구하고 있는 주요 전략 중 하나는 신생아에게 단클론 항체를 투여하여 수동 면역을 유도하는 것입니다. 파이프라인에 있는 신약들은 Synagis와 임산부 백신 접종을 통해 영아에게 수동 면역을 제공하는 기존 방식보다 우수한 성능을 보입니다. 새로운 작용 기전, 저렴한 비용, 단 한 번의 주사로 한 시즌 동안 보호 효과를 제공하는 점, 그리고 즉각적인 질병 예방 효과 등이 시장 성장을 촉진할 것으로 예상됩니다.
예를 들어, 2022년 4월 7일에 제안된 인수는 화이자의 감염성 질환 연구 개발 역량을 확장하여 호흡기 세포융합 바이러스(RSV) 감염 치료를 통해 환자 결과를 개선하고 백신 접종을 통해 질병을 예방하는 데 도움이 되는 보완적인 전략을 제공합니다. 화이자의 독자적인 항감염제 포트폴리오가 확장되고 있으며, 회사의 연구 개발, 제조 및 상업화 전문성을 활용하여 RSV 치료에 대한 상당한 미충족 수요를 충족할 것입니다. 결과적으로, 주요 제약 회사들이 RSV 치료를 위한 새로운 약물에 집중함에 따라 시장 성장이 촉진될 것입니다.
하지만 높은 질병 관리 비용은 시장 성장을 저해할 것입니다.
RSV 관리 비용이 높아 시장 성장을 제한할 것으로 예상됩니다. 미국 국립의학도서관(NLM)에 따르면, 메디케이드(Medicaid)는 신생아 RSV 입원 치료비의 61%를 부담했습니다. 메디케이드는 신생아 RSV 입원 치료비의 51%를 부담했지만, 민간 보험보다 입원당 32% 적은 금액을 지불했습니다. 영아 RSV 치료 비용은 연간 7억 960만 달러이며, 이는 출생아 1인당 평균 187달러, 공공 의료보험으로 지원되는 출산 1건당 227달러에 해당합니다. 이러한 요인은 전 세계 RSV 시장의 성장을 더욱 저해할 수 있습니다.
코로나19 영향 분석
코로나19가 호흡기세포융합바이러스(RSV)에 미치는 영향은 복잡합니다. 코로나19 팬데믹 기간 동안 RSV의 역학과 임상 양상은 급격하게 변화했습니다. 마스크 착용, 사회적 거리두기, 손 위생 개선 등 코로나19 전파를 줄이기 위한 비약물적 접근법은 RSV 감염 사례를 크게 감소시켰습니다.
코로나19가 RSV 감염에 미치는 영향은 RSV 감염의 재발과 영향을 제한하기 위한 지속적인 감시, 대비 태세, 그리고 효율적인 예방 및 치료 전략 개발의 중요성을 강조합니다.

러시아-우크라이나 전쟁 영향 분석
러시아-우크라이나 분쟁은 해당 지역의 주요 시장 참여자 수가 적기 때문에 전 세계 호흡기 세포융합 바이러스(RSV) 치료제 시장에 중간 정도의 영향을 미칠 것으로 예상됩니다. 그러나 원자재 수출입의 영향은 예측 기간 동안 전 세계 RSV 치료제 시장 성장에 미미한 영향을 미칠 것으로 예상됩니다.
인공지능(AI) 영향 분석
인공지능은 전 세계 RSV 치료제 시장 성장에 긍정적인 영향을 미칠 것으로 예상됩니다. AI는 대규모 화학 라이브러리의 가상 스크리닝에 사용되어 특정 바이러스 표적에 결합할 가능성이 있는 분자를 식별할 수 있습니다. 연구원들은 계산 모델과 알고리즘을 사용하여 수천 또는 수백만 개의 화합물의 결합 친화도를 예측하고 추가 테스트를 위한 유망한 후보 물질을 식별할 수 있습니다.
세분화 분석
전 세계 RSV 치료제 시장은 약물 유형, 제형, 치료 유형, 유통 채널 및 지역별로 세분화됩니다.

유통 채널 부문 중 병원 약국이 시장 점유율 41.3%를 차지합니다.
RSV 감염은 신생아와 영유아에게 흔하기 때문에, 이들 연령대의 환자들은 24시간 면밀한 모니터링이 필요하며, 이로 인해 RSV 감염 환자의 입원율이 높습니다. 미국에서는 RSV가 겨울과 봄철에 더 흔하게 발생합니다. RSV는 대부분의 소아 및 신생아에서 외래 진료로 치료가 가능한 바이러스입니다. 그러나 RSV에 감염된 소아 및 신생아의 0.5~2%는 입원이 필요할 수 있습니다.
예를 들어, 미국 질병통제예방센터(CDC)에 따르면, 미국에서는 매년 5세 미만 아동이 RSV로 인해 약 240만 건의 외래 진료(입원하지 않음)를 받습니다. 이 중 6만~9만 건은 5세 미만 아동의 입원 사례이며, 65세 이상 노인의 경우 5만~15만 건의 입원 사례가 발생합니다. 결과적으로 이러한 수치는 병원 약국 부문의 성장을 견인할 것입니다.
지역 분석
아시아 태평양 지역, 시장 점유율 약 22.4% 차지
높은 인구 밀도와 급증하는 감염성 질환 발생률로 인해 아시아 태평양 지역의 호흡기 세포융합 바이러스(RSV) 진단 시장은 예측 기간 동안 가장 빠르게 성장할 것으로 예상됩니다. 정확하고 신속한 질병 진단을 위한 자동화된 의료 검사에 대한 강력한 수요가 지역 시장 확장을 촉진할 것으로 전망됩니다.
의료 시스템 발전과 정부 프로그램 증가로 인해 중국, 인도, 일본, 말레이시아는 이 지역에서 가장 빠르게 성장하는 시장이 될 가능성이 높습니다. 또한 신생아 인구 증가도 시장 성장을 견인할 것으로 예상됩니다.
예를 들어, TheWorldCounts에 따르면 매년 전 세계적으로 1억 4천만 명 이상의 신생아가 태어납니다. 매초 4명 이상의 아기가 태어납니다. 매년 아시아는 전 세계 출생아 수의 절반 이상을 차지하며, 인도에서만 2천 5백만 명, 중국에서만 1천 6백만 명이 태어납니다. 이러한 지표들은 아시아 태평양 지역이 시장을 주도할 것임을 시사합니다.

경쟁 환경
시장의 주요 글로벌 업체로는 Sanofi, GSK plc, Pfizer, AstraZeneca, AbbVie, Bausch Health Companies, Bavarian Nordic, Merck & Co, Moderna, Inc., mAbxience 등이 있습니다.
보고서 구매 이유

• 감염 유형, 약물 유형, 최종 사용자 및 지역별 글로벌 호흡기 세포융합 바이러스(RSV) 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 RSV 치료제 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석을 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 Excel 파일을 제공합니다.

글로벌 RSV 치료제 시장 보고서는 약 53개의 표, 54개의 그림, 195페이지 분량입니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Respiratory Syncytial Virus (RSV) Therapeutics Market reached US$ 1.2 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.4 billion by 2030. The global Respiratory Syncytial Virus (RSV) therapeutics market is expected to exhibit a CAGR of 10.2% during the forecast period (2023-2030). The increasing hospital admissions and the growing clinical trialsfor novel drugs are driving up demand for respiratory syncytial virus therapeutics market trends.
Respiratory Syncytial Virus (RSV) is a common viral infection that mostly affects newborns and young children's respiratory systems. RSV can also cause serious respiratory infection in elderly people and those with compromised immune systems. RSV is the most common cause of hospitalisation among babies and young children. Effective therapies may lessen the severity of the infection, reduce the need for hospitalization, and so reduce the pressure on healthcare systems.
Market Dynamics
Rise in the Clinical Trials by the Key Players is expected to Drive the Market Growth
The increase in clinical trials by key companies is projected to fuel market growth. For instance, May 8, 2023, The China National Medical Products Administration ("NMPA") has approved a Phase IIa clinical trial for ASC10 to treat respiratory syncytial virus (RSV) infection, according to Ascletis Pharma Inc.
Based on the available results, a dose of 800 mg ASC10 twice daily was chosen for a randomised, double-blind, placebo-controlled Phase IIa research to assess the antiviral efficacy, safety, tolerability, and pharmacokinetics of ASC10 tablets in patients with mild or moderate RSV infection. Clinical trials will also increase market growth.
Strong Pipeline of Products Showing Promising Results to Propel market growth
One of the primary tactics being investigated by pharmaceutical companies in their fight against RSV is the use of monoclonal antibodies in newborns to cause passive immunisation. The pipeline items outperform Synagis and the alternative technique of vaccination pregnant moms to deliver passive immunisation to infants. Novel mechanisms, cheaper costs, and protection for the full season with a single injection, as well as instant disease prevention, are expected to boost market growth.
For instance, on April 07, 2022, the proposed acquisition expands Pfizer's infectious disease research and development capabilities by providing a complementary strategy to help improve patient outcomes through treatment for respiratory syncytial virus (RSV) infections and prevent sickness through vaccination. Pfizer's unique anti-infective portfolio is being expanded, and the company's R&D, manufacturing, and commercialization expertise is being used to meet a substantial unmet demand for RSV treatments. As a result, prominent manufacturers' focus on novel medications to treat RSV will fuel market expansion.
High Cost of Disease Management will hamper the market growth.
The cost of managing RSV is high, which is expected to limit market growth. According to the NLM, Medicaid covered 61% of newborn RSVHs. Medicaid covered 51% of baby RSVH costs, paying 32% less per hospitalisation than commercial insurance. RSV therapy for infants costs $709.6 million per year, or $187 per total birth and $227 every publicly financed delivery. This factor may further hinder the global RSV market's progress.
COVID-19 Impact Analysis
The effect of COVID-19 on Respiratory Syncytial Virus (RSV) has been complicated. During the COVID-19 pandemic, RSV epidemiology and clinical patterns changed dramatically. Non-pharmaceutical approaches aimed at reducing COVID-19 transmission, including as mask use, social distancing, and improved hand hygiene, resulted in a considerable decrease in RSV cases.
The influence of COVID-19 on RSV infection has highlighted the importance of ongoing surveillance, readiness, and the development of efficient preventative and therapeutic strategies to limit the recurrence and impact of RSV infections.
Russia-Ukraine War Impact Analysis
The Russia-Ukraine conflict is estimated to have a moderate impact on the global respiratory syncytial virus therapeutics market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global respiratory syncytial virus therapeutics market growth over the forecast period.
Artificial Intelligence Impact Analysis
Artificial intelligence is anticipated to impact the growth of global respiratory syncytial virus therapeutics market positively. AI can be used for virtual screening of large chemical libraries to identify molecules with the potential to bind to specific viral targets. By using computational models and algorithms, researchers can predict the binding affinity of thousands or millions of compounds, allowing them to identify promising candidates for further testing
Segment Analysis
The global respiratory syncytial virus therapeutics market is segmented based on drug type, dosage form, treatment type, distribution channel and region.
Hospital Pharmacy from Distribution Channel Segment Accounts for 41.3% of Market Share
Because RSV infection is common in neonates and infants, therapy for these populations must be closely monitored around the clock, resulting in a high hospitalisation rate in cases of RSV infection. RSV is more common in the winter and spring months in the United States. RSV is a virus that can be treated on an outpatient basis in the majority of children and newborns. However, between 0.5 to 2% of children and newborns with RSV may require hospitalisation.
For instance, according to CDC, RSV causes approximately 2.4 million outpatient (non-hospitalization) visits among children under the age of five in the United States each year. 60,000-90,000 hospitalisations among children under the age of five. In addition, 50,000-150,000 hospitalisations among aged 65 and older. As a result, those figures will drive the growth of the hospital pharmacy segment.
Geographical Analysis
Asia Pacific Accounted for Approximately 22.4% of the Market Share
Due to the high population density and rapidly increasing frequency of infectious disorders, the Asia Pacific respiratory syncytial virus diagnostics market is predicted to develop the fastest over the forecast period. Strong need for automated healthcare testing for accurate and faster disease diagnosis is projected to drive regional market expansion.
Due to rising healthcare systems and an increasing number of government programmes, China, India, Japan, and Malaysia are likely to be the region's fastest-growing markets. Furthermore, the expanding newborn population is likely to drive market growth.
For instance, according to TheWorldCounts, Every year, over 140 million infants are born around the world. Every second, more than four babies are born. Every year, Asia accounts for more than half of global births, with 25 million births in India and 16 million births in China alone. These indicators indicate that Asia Pacific will dominate the market.
Competitive Landscape
The major global players in the market include Sanofi, GSK plc, Pfizer, AstraZeneca, AbbVie, Bausch Health Companies, Bavarian Nordic, Merck & Co, Moderna, Inc., and mAbxience, among others.
Why Purchase the Report?
• To visualize the global respiratory syncytial virus therapeutics market segmentation based on infection type, drug type, end user and region,as well as understandkey commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of respiratory syncytial virus therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global respiratory syncytial virus therapeutics market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by Dosage Form
3.3. Snippet by Treatment Type
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the Clinical Trails by the Key Players
4.1.1.2. Strong Pipeline of Products Showing Promising Results
4.1.2. Restraints
4.1.2.1. High Cost of Disease Management
4.1.3. Opportunity
4.1.3.1. Development of effective treatments to combat and prevent RSV infections
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario before COVID-19
6.1.2. Scenario during COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Impact Analysis
9. By Drug Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.1.2. Market Attractiveness Index, By Drug Type
9.2. Ribavirin
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Nirsevimab
9.4. Virazole
9.5. Palivizumab
9.6. Riba Tab
9.7. Others
10. By Dosage Form
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
10.1.2. Market Attractiveness Index, By Dosage Form
10.2. Oral
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Injectable
10.4. Inhaler
10.5. Others
11. By Treatment Type
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.1.2. Market Attractiveness Index, By Treatment Type
11.2. Immune prophylaxis
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Supportive care
11.4. Antiviral Medications
12. By Distribution Channel
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.1.2. Market Attractiveness Index, By Distribution Channel
12.2. Hospital Pharmacy
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Retail Pharmacy
12.4. Online Pharmacy
13. By Region
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.7.1. The U.S.
13.2.7.2. Canada
13.2.7.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.7.1. Germany
13.3.7.2. The U.K.
13.3.7.3. France
13.3.7.4. Italy
13.3.7.5. Spain
13.3.7.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.7.1. Brazil
13.4.7.2. Argentina
13.4.7.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.7.1. China
13.5.7.2. India
13.5.7.3. Japan
13.5.7.4. Australia
13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14. Competitive Landscape
14.1. Competitive Scenario
14.2. Market Share Analysis
14.3. Mergers and Acquisitions Analysis
15. Company Profiles
15.1. Sanofi
15.1.1. Company Overview
15.1.2. Type Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. GSK plc
15.3. Pfizer
15.4. AstraZeneca
15.5. AbbVie
15.6. Bausch Health Companies
15.7. Bavarian Nordic
15.8. Merck & Co
15.9. Moderna, Inc.
15.10. mAbxience.
LIST NOT EXHAUSTIVE
16. Appendix
16.1. About Us and Services
16.2. Contact Us

언급된 주요 기업들

Sanofi, 4.	Key Developments, GSK plc, Pfizer, AstraZeneca, AbbVie, Bausch Health Companies, Bavarian Nordic, Merck & Co, Moderna, Inc., mAbxience.

표 목록 (Tables)

List of Tables

Table 1 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Dosage Form, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Billion)

Table 7 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 8 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Dosage Form, 2022, 2026 & 2030 (US$ Billion)

Table 9 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Dosage Form, 2021-2030 (US$ Billion)

Table 10 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Billion)

Table 11 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Treatment Type, 2021-2030 (US$ Billion)

Table 12 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 13 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 14 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 15 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Region, 2021-2030 (US$ Billion)

Table 16 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 17 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Dosage Form, 2021-2030 (US$ Billion)

Table 18 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Treatment Type, 2021-2030 (US$ Billion)

Table 19 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 20 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 South America Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 22 South America Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Dosage Form, 2021-2030 (US$ Billion)

Table 23 South America Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Treatment Type, 2021-2030 (US$ Billion)

Table 24 South America Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 25 South America Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Country, 2021-2030 (US$ Billion)

Table 26 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 27 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Dosage Form, 2021-2030 (US$ Billion)

Table 28 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Treatment Type, 2021-2030 (US$ Billion)

Table 29 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 30 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Country, 2021-2030 (US$ Billion)

Table 31 Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 32 Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Dosage Form, 2021-2030 (US$ Billion)

Table 33 Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Treatment Type, 2021-2030 (US$ Billion)

Table 34 Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 35 Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Country, 2021-2030 (US$ Billion)

Table 36 Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 37 Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Dosage Form, 2021-2030 (US$ Billion)

Table 38 Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Treatment Type, 2021-2030 (US$ Billion)

Table 39 Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 40 Sanofi: Overview

Table 41 Sanofi: Product Portfolio

Table 42 Sanofi: Key Developments

Table 43 GSK plc: Overview

Table 44 GSK plc: Product Portfolio

Table 45 GSK plc: Key Developments

Table 46 Pfizer: Overview

Table 47 Pfizer: Product Portfolio

Table 48 Pfizer: Key Developments

Table 49 AstraZeneca: Overview

Table 50 AstraZeneca: Product Portfolio

Table 51 AstraZeneca: Key Developments

Table 52 AbbVie: Overview

Table 53 AbbVie: Product Portfolio

Table 54 AbbVie: Key Developments

Table 55 Bausch Health Companies: Overview

Table 56 Bausch Health Companies: Product Portfolio

Table 57 Bausch Health Companies: Key Developments

Table 58 Bavarian Nordic: Overview

Table 59 Bavarian Nordic: Product Portfolio

Table 60 Bavarian Nordic: Key Developments

Table 61 Merck & Co: Overview

Table 62 Merck & Co: Product Portfolio

Table 63 Merck & Co: Key Developments

Table 64 Moderna, Inc.: Overview

Table 65 Moderna, Inc.: Product Portfolio

Table 66 Moderna, Inc.: Key Developments

Table 67 mAbxience: Overview

Table 68 mAbxience: Product Portfolio

Table 69 mAbxience: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Drug Type, 2022 & 2030 (%)

Figure 3 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Dosage Form, 2022 & 2030 (%)

Figure 4 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 5 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 6 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Y-o-Y Growth, By Drug Type, 2022-2030 (%)

Figure 8 Ribavirin Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 9 Nirsevimab Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 10 Virazole Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 11 Palivizumab Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 12 Riba Tab Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 13 Others Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 14 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Y-o-Y Growth, By Dosage Form, 2022-2030 (%)

Figure 15 Oral Dosage Form in Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 16 Injectable Dosage Form in Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 17 Inhaler Dosage Form in Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 18 Others Dosage Form in Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 19 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Y-o-Y Growth, By Treatment Type, 2022-2030 (%)

Figure 20 Immune prophylaxis Treatment Type in Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 21 Supportive care Treatment Type in Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 22 Antiviral Medications Treatment Type in Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 23 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 24 Hospital Pharmacy Distribution Channel in Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 25 Retail Pharmacy Distribution Channel in Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 26 Online Pharmacy Distribution Channel in Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 27 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 28 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 29 Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 30 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 31 South America Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 32 Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 33 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 34 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Drug Type, 2022 & 2030 (%)

Figure 35 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Dosage Form, 2022 & 2030 (%)

Figure 36 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 37 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 38 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Country, 2022 & 2030 (%)

Figure 39 South America Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 40 South America Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Drug Type, 2022 & 2030 (%)

Figure 41 South America Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Dosage Form, 2022 & 2030 (%)

Figure 42 South America Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 43 South America Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 44 South America Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Country, 2022 & 2030 (%)

Figure 45 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 46 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Drug Type, 2022 & 2030 (%)

Figure 47 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Dosage Form, 2022 & 2030 (%)

Figure 48 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 49 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 50 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Country, 2022 & 2030 (%)

Figure 51 Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 52 Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Drug Type, 2022 & 2030 (%)

Figure 53 Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Dosage Form, 2022 & 2030 (%)

Figure 54 Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 55 Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 56 Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Country, 2022 & 2030 (%)

Figure 57 Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value, 2021-2030 (US$ Billion)

Figure 58 Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Drug Type, 2022 & 2030 (%)

Figure 59 Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Dosage Form, 2022 & 2030 (%)

Figure 60 Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 61 Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 62 Sanofi: Financials

Figure 63 GSK plc: Financials

Figure 64 Pfizer: Financials

Figure 65 AstraZeneca: Financials

Figure 66 AbbVie: Financials

Figure 67 Bausch Health Companies: Financials

Figure 68 Bavarian Nordic: Financials

Figure 69 Merck & Co: Financials

Figure 70 Moderna, Inc.: Financials

Figure 71 mAbxience: Financials

세계 호흡기세포융합바이러스(RSV) 치료제 시장 – 2023-2030

Global Respiratory Syncytial Virus (RSV) Therapeutics Market - 2023-2030